Novo Nordisk Reports DKK 6.3B Non-Recurring, Non-Cash Impairment Charges In Q2 Related To Intangible Pipeline Assets
https://www.novonordisk.com/news-and-media/news-and-ir-materials/news-details.html?id=916590
Novo Nordisk wrote down the value of some future medicine projects on paper—meaning they think those projects are worth less than they thought before. When a company takes a big write-down like this, it's worth noticing what changed in their plans, but one-time paper losses don't always say much about whether the business is doing well right now.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.